Close Menu

Trying to determine what journal to submit her paper to, ScienceWoman does her research. Considering things like time to publication and impact factor, she makes some graphs and charts of her decision-making process. Some of the comments advise her to try PLoS ONE, but she's not sure, since she's still a junior investigator and doesn't think her type of research has seen publication there before. "Sure, I could be the first, but as a junior academic, I need to have people in my field reading my papers.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.

The New York Times reports that a new viral variant of concern has been identified in New York City.

In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.